
|Articles|July 6, 2018
Migraine News Highlights AJPB Week in Review
Author(s)AJPB staff
Top news of the week from The American Journal of Pharmacy Benefits.
Advertisement
5. Immunotherapy Treatment Improves PFS in Advanced Triple-Negative Breast Cancer
Atezolizumab (Tecentriq) plus chemotherapy nab-paclitaxel (Abraxane) significantly reduced the risk of disease worsening or death in patients with metastatic triple-negative breast cancer. Read more.
4. Pain Societies Create Consensus Guidelines for Use of Ketamine in Pain Management
Three pain societies have come together to create consensus guidelines for treating both acute and chronic pain with ketamine, an old drug seeing a resurgence. Read more.
3. Coffee and Chocolate May Trigger Migraines
As researchers examined what food and drinks were most commonly linked to migraine and tension-type headache in Malaysian patients, they found that coffee and chocolate were reported most often. Read more.
2. Estrogen Levels May Play a Role in Migraine Prevalence in Men
A study of 39 men found that those affected by migraine had higher levels of estradiol, an estrogen, than those without migraine. Read more.
1. Trial Demonstrates Positive Long-Term Efficacy and Safety for Migraine Drug
Amgen and Novartis have announced positive long-term efficacy, safety, and tolerability data of erenumab-aooe (Aimovig) in patients with chronic and episodic migraine. Read more.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Earlier Menopause, Reduced Cardiac Function Potentially Linked With Negative Impacts on Brain Health
2
A Multifaceted Approach to Navigating Career Transitions in Pharmacy
3
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
4
Menopause Care Varies by Provider, Highlighting Need for Standardized Education
5













































































































































































































